Table 3 Summary of performance... | American Society of Hematology

Table 3

Summary of performance characteristics in terms of the differences in BCR-ABL values compared to the reference method of the 19 field methods that have undertaken the conversion factor validation procedure for their current analytical system

Field method	Control gene	RQ-PCR reference	Conversion factor	Number of validation samples	Average difference before conversion (fold)	Average difference after conversion (fold)	95% limits of agreement after conversion
Field method	Control gene	RQ-PCR reference	Conversion factor	Number of validation samples	Average difference before conversion (fold)	Average difference after conversion (fold)	Lower (fold)	Upper (fold)
1	ABL	22,23	1.35	21 trizol	−1.1	1.0	−2.7	+2.7
2	BCR	2	1.13	26 trizol	−1.1	−1.2	−2.7	+2.3
3	B2M	In house	10.23	17 RNA	−7.2	+1.1	−2.4	+2.6
4	BCR	2	1.7	16 trizol	+1.1	+1.2	−2.5	+2.9
5	BCR	2	1.05	17 trizol	+1.0	−1.2	−3.3	+2.9
6	BCR	2	1.28	58 RNA	−1.1	−1.1	−3.5	+3.3
7	ABL	In house	0.18	14 RNA	+8.1	+1.2	−3.4	+3.8
8	ABL	22,23	0.56	20 trizol	+1.6	+1.2	−3.5	+3.9
9	ABL	1	0.88	26 RNA, 22 trizol	+1.4	1.0	−4.3	+4.3
10	BCR	In house	10.2	20 RNA	−6.0	−1.2	−4.6	+4.2
11	ABL	22,23	0.23	61 RNA	+4.4	−1.2	−4.9	+4.5
12	ABL	In house	7.78	15 RNA	−7.7	−1.2	−5.2	+4.8
13	ABL	22,23	0.36	22 trizol	+4.4	+1.2	−5.2	+4.8
14	ABL	22,23	0.56	73 RNA	+2.9	+1.3	−4.5	+5.1
15	ABL	22,23	0.79	32 RNA	+1.7	+1.2	−5.8	+5.9
16	BCR	3,8	2.39	61 RNA, 32 trizol	−2.0	−1.2	−6.1	+5.9
17	BCR	In house	0.42	14 trizol	+2.5	−1.2	−7.0	+6.6
18	GUS	1,25	2.14	17 trizol	−1.7	+1.2	−7.6	+8.0
19	GUS	22,23	0.61	14 trizol	+4.2	+2.1	−2.7	+4.9

Field method	Control gene	RQ-PCR reference	Conversion factor	Number of validation samples	Average difference before conversion (fold)	Average difference after conversion (fold)	95% limits of agreement after conversion
Field method	Control gene	RQ-PCR reference	Conversion factor	Number of validation samples	Average difference before conversion (fold)	Average difference after conversion (fold)	Lower (fold)	Upper (fold)
1	ABL	22,23	1.35	21 trizol	−1.1	1.0	−2.7	+2.7
2	BCR	2	1.13	26 trizol	−1.1	−1.2	−2.7	+2.3
3	B2M	In house	10.23	17 RNA	−7.2	+1.1	−2.4	+2.6
4	BCR	2	1.7	16 trizol	+1.1	+1.2	−2.5	+2.9
5	BCR	2	1.05	17 trizol	+1.0	−1.2	−3.3	+2.9
6	BCR	2	1.28	58 RNA	−1.1	−1.1	−3.5	+3.3
7	ABL	In house	0.18	14 RNA	+8.1	+1.2	−3.4	+3.8
8	ABL	22,23	0.56	20 trizol	+1.6	+1.2	−3.5	+3.9
9	ABL	1	0.88	26 RNA, 22 trizol	+1.4	1.0	−4.3	+4.3
10	BCR	In house	10.2	20 RNA	−6.0	−1.2	−4.6	+4.2
11	ABL	22,23	0.23	61 RNA	+4.4	−1.2	−4.9	+4.5
12	ABL	In house	7.78	15 RNA	−7.7	−1.2	−5.2	+4.8
13	ABL	22,23	0.36	22 trizol	+4.4	+1.2	−5.2	+4.8
14	ABL	22,23	0.56	73 RNA	+2.9	+1.3	−4.5	+5.1
15	ABL	22,23	0.79	32 RNA	+1.7	+1.2	−5.8	+5.9
16	BCR	3,8	2.39	61 RNA, 32 trizol	−2.0	−1.2	−6.1	+5.9
17	BCR	In house	0.42	14 trizol	+2.5	−1.2	−7.0	+6.6
18	GUS	1,25	2.14	17 trizol	−1.7	+1.2	−7.6	+8.0
19	GUS	22,23	0.61	14 trizol	+4.2	+2.1	−2.7	+4.9

View Large

This Feature Is Available To Subscribers Only